COVID-19 clinical trial disruption declines but trials continue to suffer from slow recruitment Read more
Umifenovir addition gives no significant clinical benefit in COVID-19 treatment: Glenmark study Read more
Beyond highly developed pharma markets! Wild card access to less explored, high entry barrier territories Read more
India, South Africa call for waiver of IP, patents under certain TRIPS provisions for COVID-19 therapeutics Read more